| 29.05 12:57 | dpa-AFX: Merck To Acquire EyeBio; Deal Valued Up To $3 Bln |
| 29.05 12:51 | dpa-AFX: *MERCK SEES EYEBIO DEAL TO RECORD A CHARGE OF ABOUT $1.3 BLN, OR ABOUT $0.50 PER SHARE |
| 29.05 12:50 | dpa-AFX: *MERCK SEES EYEBIO DEAL TO CLOSE IN Q3 OF 2024 |
| 29.05 12:49 | dpa-AFX: *MERCK & CO KAUFT FÜR BIS ZU 1,7 MRD USD AUGENFIRMA EYEBIO |
| 29.05 12:48 | dpa-AFX: *MERCK TO ACQUIRE EYEBIO FOR UP TO $3 BLN |
| 29.05 12:15 | MARKT USA/Zinsanstieg sorgt für Vorsicht bei Aktien |
| 29.05 04:09 | dpa-AFX: Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report |
| 28.05 13:14 | dpa-AFX: Merck Reports Positive Phase 3 KEYTRUDA Plus Chemotherapy Trial Results In TNBC Patients |
| 28.05 12:50 | dpa-AFX: *MERCK SAYS PHASE 3 KEYNOTE-522 TRIAL OF KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY MEETS OVERALL SURVIVAL ENDPOINT |
| 13.05 13:07 | dpa-AFX: Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma |
| 13.05 12:50 | dpa-AFX: *MERCK ANNOUNCES DISCONTINUATION OF VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION ARM OF PHASE 3 KEYVIBE-010 TRIAL |
| 09.05 16:02 | MÄRKTE USA/Weiter wenig Bewegung - Arm sehr schwach |
| 09.05 15:27 | dpa-AFX: Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal |
| 09.05 14:59 | MÄRKTE USA/Weiter wenig Bewegung - Arm sehr schwach |
| 09.05 14:39 | dpa-AFX: *MERCK : PHASE 3 TRIAL OF KEYTRUDA PLUS CHEMOTHERAPY IN ENDOMETRIAL CANCER FAILS TO MEET MAIN GOAL |
| 09.05 13:49 | dpa-AFX: Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults |
| 09.05 13:07 | dpa-AFX: *MERCK: HEALTH CANADA APPROVES KEYTRUDA + GEMCITABINE-BASED CHEMOTHERAPY FOR BILIARY TRACT CARCINOMA IN ADULTS |
| 30.04 16:22 | dpa-AFX: *LBBW HEBT ZIEL FÜR MERCK & CO AUF 130 (125) USD - 'HALTEN' |
| 30.04 16:22 | dpa-AFX: *LBBW RAISES MERCK & CO PRICE TARGET TO 130 (125) USD - 'HOLD' |
| 29.04 07:20 | ROUNDUP: 'Pharma-Reise' von Habeck - Branche sieht strukturelle Probleme |
|
|
